The direct trial (daily-dose consensus interferon and ribavirin: efficacy of combined therapy): Treatment of non-responders to previous pegylated interferon plus ribavirin: Sustained virologic response data

被引：0
|
作者：
Bacon, Bruce
Regev, Arie
Ghalib, Reem H.
Morelli, Giuseppe
Rothstein, Kenneth D.
Shiffman, Mitchell L.
Hossanein, Tarek
Hammond, Janet
机构：
[1] St Louis Univ, Sch Med, Liver Ctr, St Louis, MO 63103 USA
[2] Univ Miami, Coral Gables, FL 33124 USA
[3] Methodist Hosp, Liver Inst, Dallas, TX USA
[4] Univ Florida, Gainesville, FL 32611 USA
[5] Albert Einstein Ctr Liver Dis, Philadelphia, PA USA
[6] Virginia Commonwealth Univ, Richmond, VA 23284 USA
[7] Univ Calif San Diego, La Jolla, CA 92093 USA
[8] Valeant Pharmaceut N Amer, Aliso Viejo, CA USA
来源：
HEPATOLOGY | 2007年 / 46卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
168
引用
收藏
页码：311A / 312A
页数：2
相关论文
共 50 条
  • [41] A randomized trial of ribavirin and interferon-α vs. interferon-α alone in patients with chronic hepatitis C who were non-responders to a previous treatment
    Pol, S
    Couzigou, P
    Bourlière, M
    Abergel, A
    Combis, JM
    Larrey, D
    Tran, A
    Moussalli, J
    Poupon, R
    Berthelot, P
    Bréchot, C
    JOURNAL OF HEPATOLOGY, 1999, 31 (01) : 1 - 7
  • [42] High efficacy of combined therapy with pegylated interferon plus ribavirin in patients with hemophilia and chronic hepatitis C
    Mancuso, Maria Elisa
    Rumi, Maria Grazia
    Santagostino, Elena
    Linari, Silvia
    Coppola, Antonio
    Mannucci, Pier Mannuccio
    Colombo, Massimo
    Rocino, A.
    Iorio, A.
    Dragani, A.
    Barillari, G.
    Tagariello, G.
    Nicolin, R.
    HAEMATOLOGICA, 2006, 91 (10) : 1367 - 1371
  • [43] Retreatment with interferon plus ribavirin of chronic hepatitis C non-responders to interferon monotherapy:: a meta-analysis of individual patient data
    Cammà, C
    Bruno, S
    Schepis, F
    Lo Iacono, O
    Andreone, P
    Gramenzi, AG
    Mangia, A
    Andriulli, A
    Puoti, M
    Spadaro, A
    Freni, M
    Di Marco, V
    Cino, L
    Saracco, G
    Chiesa, A
    Crosignani
    Caporaso, N
    Morisco, F
    Rumi, MG
    Craxì, A
    GUT, 2002, 51 (06) : 864 - 869
  • [44] EFFICACY AND SAFETY OF AN INTENSIFIED REGIMEN OF PEGYLATED INTERFERON ALFA-2A PLUS RIBAVIRIN (RBV) IN HCV GENOTYPE 1 NON-RESPONDERS: FINAL RESULTS OF THE SYREN TRIAL
    Hezode, Christophe
    Foucher, Juliette
    Bronowicki, Jean-Pierre
    Leroy, Vincent
    Tran, Albert
    Larrey, Dominique
    Mathurin, Philippe
    Rosa, Isabelle
    Alric, Laurent
    Barrault, Camille
    Nani, Abdelbasset
    Bouvier-Alias, Magali
    Rouanet, Stephanie
    Couzigou, Patrice
    Mallat, Ariane
    Eddine, Mariem Charaf
    Pawlotsky, Jean-Michel
    HEPATOLOGY, 2010, 52 (04) : 718A - 718A
  • [45] The effect of amantadine on sustained virologic response when added to pegylated interferon alfa 2b plus weight based ribavirin in previous nonresponders and relapsers
    Lawitz, EJ
    Harrison, SA
    Cantu, NS
    Kadakia, SC
    Ganeshappa, KP
    Adams, F
    Davis, M
    Sperling, R
    Tsai, N
    Gasic, A
    Kothari, T
    Cox, J
    Sanders, B
    Silverman, B
    Ghandour, E
    Medoff, J
    Prasad, V
    Afdahl, N
    Mailliard, M
    Curry, M
    GASTROENTEROLOGY, 2004, 126 (04) : A697 - A697
  • [46] Usefulness of viral kinetics for early prediction of a sustained virological response in HCV-1 non-responders re-treated with pegylated interferon and ribavirin
    Deltenre, Pierre
    Corouge, Marion
    Canva, Valerie
    Castel, Helene
    Wartel, Faustine
    Dharancy, Sebastien
    Louvet, Alexandre
    Lazrek, Mouna
    Moreno, Christophe
    Henrion, Jean
    Mathurin, Philippe
    JOURNAL OF HEPATOLOGY, 2011, 55 (05) : 989 - 995
  • [47] The efficacy of an interferon dose escalation scheme. Combined with ribavirin, for the treatment of interferon refractory hepatitis C: An interim analysis of end of treatment virologic response.
    Navarro, VJ
    Polio, J
    Bonheim, N
    Gupta, T
    Fiorito, J
    Tummillo, K
    St Louis, T
    Bonis, PP
    GASTROENTEROLOGY, 2000, 118 (04) : A1472 - A1472
  • [48] Combination treatment with consensus-interferon and ribavirin for chronic hepatitis C patients with non-response relapse to previous treatment with alpha-interferon and ribavirin.
    Buggisch, P
    Seegers, B
    Hinrichsen, H
    Hueppe, D
    Reiser, M
    de Heer, G
    Wursthorn, K
    Sterneck, M
    HEPATOLOGY, 2002, 36 (04) : 363A - 363A
  • [49] Retreatment of standard interferon/ribavirin non-responder patients with chronic hepatitis C with daily consensus interferon and ribavirin yields high sustained response rates.
    Kaiser, S
    Hass, HG
    Gregor, M
    HEPATOLOGY, 2003, 38 (04) : 276A - 276A
  • [50] Sustained virologic response rates from a randomized trial of HCV genotype-1 subjects treated with either consensus IFN and ribavirin or pegylated interferon alfa-2b and ribavirin
    Sjogren, M
    Sjogren, R
    Lyons, MF
    Ryan, M
    Santoro, J
    Smith, C
    Reddy, KR
    Bonkovsky, H
    Huntley, BM
    Ibarra, L
    Faris-Young, S
    HEPATOLOGY, 2005, 42 (04) : 529A - 530A
12345